{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T20:07:22Z","timestamp":1783541242681,"version":"3.55.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"National Institute for Health Research Newcastle Biomedical Research Centre"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.clinthera.2019.04.020","type":"journal-article","created":{"date-parts":[[2019,6,9]],"date-time":"2019-06-09T23:59:13Z","timestamp":1560124753000},"page":"1312-1322","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Potential Pharmacologic Targets for the Prevention of Rheumatoid Arthritis"],"prefix":"10.1016","volume":"41","author":[{"given":"John D.","family":"Isaacs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kundan","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2019.04.020_bib1","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1136\/annrheumdis-2011-200990","article-title":"EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis","volume":"71","author":"Gerlag","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2019.04.020_bib2","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.clinthera.2019.04.028","article-title":"Natural history of rheumatoid arthritis","volume":"41","author":"Deane","year":"2019","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2019.04.020_bib3","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1136\/annrheumdis-2016-209846","article-title":"EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis","volume":"76","author":"van Steenbergen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2019.04.020_bib4","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.clinthera.2019.04.021","article-title":"Potential of lifestyle changes for reducing the risk of developing rheumatoid arthritis: is an ounce of prevention worth a pound of cure?","volume":"41","author":"Zaccardelli","year":"2019","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2019.04.020_bib5","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.clinthera.2019.04.012","article-title":"Mucosal biology and the development of rheumatoid arthritis: potential for prevention by targeting mucosal processes","volume":"41","author":"Demoruelle","year":"2019","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2019.04.020_bib6","first-page":"605","article-title":"The changing face of rheumatoid arthritis: sustained remission for all?","volume":"10","author":"Isaacs","year":"2010","journal-title":"Nat Rev"},{"key":"10.1016\/j.clinthera.2019.04.020_bib7","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jbspin.2012.01.008","article-title":"Citrullination under physiological and pathological conditions","volume":"79","author":"Baka","year":"2012","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.clinthera.2019.04.020_bib8","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s12891-016-1055-2","article-title":"Decreased severity of experimental autoimmune arthritis in peptidylarginine deiminase type 4 knockout mice","volume":"17","author":"Suzuki","year":"2016","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.clinthera.2019.04.020_bib9","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/cei.12932","article-title":"Protein arginine deiminase 4 inhibition is sufficient for the amelioration of collagen-induced arthritis","volume":"188","author":"Willis","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.clinthera.2019.04.020_bib10","doi-asserted-by":"crossref","first-page":"26430","DOI":"10.1038\/srep26430","article-title":"Abrogation of collagen-induced arthritis by a peptidyl arginine deiminase inhibitor is associated with modulation of T cell-mediated immune responses","volume":"6","author":"Kawalkowska","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.clinthera.2019.04.020_bib11","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nrrheum.2017.15","article-title":"Beyond citrullination: other post-translational protein modifications in rheumatoid arthritis","volume":"13","author":"Trouw","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.clinthera.2019.04.020_bib12","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrd.2016.84","article-title":"Bristol-Myers Squibb acquires potential keys to treating rheumatoid arthritis","volume":"15","author":"Cully","year":"2016","journal-title":"Nat Rev Drug Disc"},{"key":"10.1016\/j.clinthera.2019.04.020_bib13","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf7779","article-title":"Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes","volume":"9","author":"Alhadj Ali","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.clinthera.2019.04.020_bib14","doi-asserted-by":"crossref","first-page":"e955","DOI":"10.1212\/WNL.0000000000005118","article-title":"Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosis","volume":"90","author":"Chataway","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2019.04.020_bib15","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/80516","article-title":"Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand","volume":"6","author":"Bielekova","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.clinthera.2019.04.020_bib16","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/nature16962","article-title":"Expanding antigen-specific regulatory networks to treat autoimmunity","volume":"530","author":"Clemente-Casares","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2019.04.020_bib17","doi-asserted-by":"crossref","first-page":"E156","DOI":"10.1073\/pnas.1408686111","article-title":"Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance","volume":"112","author":"Maldonado","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinthera.2019.04.020_bib18","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/nbt.2434","article-title":"Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis","volume":"30","author":"Getts","year":"2012","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.clinthera.2019.04.020_bib19","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.jhep.2015.01.006","article-title":"Nanoparticle-based autoantigen delivery to Treg-inducing liver sinusoidal endothelial cells enables control of autoimmunity in mice","volume":"62","author":"Carambia","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.clinthera.2019.04.020_bib20","doi-asserted-by":"crossref","first-page":"290ra87","DOI":"10.1126\/scitranslmed.aaa9301","article-title":"Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype-positive rheumatoid arthritis patients","volume":"7","author":"Benham","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.clinthera.2019.04.020_bib21","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/annrheumdis-2015-208456","article-title":"Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis","volume":"76","author":"Bell","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2019.04.020_bib22","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.2337\/dc11-0472","article-title":"Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients","volume":"34","author":"Giannoukakis","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2019.04.020_bib23","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/ecco-jcc\/jjv144","article-title":"Intraperitoneal administration of autologous tolerogenic dendritic cells for refractory Crohn's disease: a phase I study","volume":"9","author":"Jauregui-Amezaga","year":"2015","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.clinthera.2019.04.020_bib24","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/annrheumdis-2018-214024","article-title":"Tolerising cellular therapies: what is their promise for autoimmune disease?","volume":"78","author":"Mosanya","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2019.04.020_bib25","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.2337\/dc12-0038","article-title":"Administration of CD4+CD25highCD127- regulatory T cells preserves beta-cell function in type 1 diabetes in children","volume":"35","author":"Marek-Trzonkowska","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2019.04.020_bib26","doi-asserted-by":"crossref","first-page":"315ra189","DOI":"10.1126\/scitranslmed.aad4134","article-title":"Type 1 diabetes immunotherapy using polyclonal regulatory T cells","volume":"7","author":"Bluestone","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.clinthera.2019.04.020_bib27","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/art.40737","article-title":"Adoptive regulatory T cell therapy in a patient with systemic lupus erythematosus","volume":"71","author":"Dall'Era","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.clinthera.2019.04.020_bib28","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1053\/j.gastro.2012.07.116","article-title":"Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease","volume":"143","author":"Desreumaux","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2019.04.020_bib29","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.3389\/fimmu.2017.01313","article-title":"Avidity and bystander suppressive capacity of human regulatory T cells expressing de novo autoreactive t-cell receptors in type 1 diabetes","volume":"8","author":"Yeh","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.clinthera.2019.04.020_bib30","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1126\/science.aau2688","article-title":"Treg cells-the next frontier of cell therapy","volume":"362","author":"Bluestone","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2019.04.020_bib31","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1136\/gutjnl-2014-306919","article-title":"Developing in\u00a0vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn's disease","volume":"65","author":"Canavan","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.clinthera.2019.04.020_bib32","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1002\/eji.200737594","article-title":"DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3(+) conventional T cells","volume":"37","author":"Baron","year":"2007","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.clinthera.2019.04.020_bib33","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.autrev.2011.05.004","article-title":"Human FoxP3+ regulatory T cells in systemic autoimmune diseases","volume":"10","author":"Miyara","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.clinthera.2019.04.020_bib34","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMoa1105143","article-title":"Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis","volume":"365","author":"Saadoun","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2019.04.020_bib35","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1136\/annrheumdis-2014-206506","article-title":"Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE","volume":"74","author":"Humrich","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2019.04.020_bib36","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/annrheumdis-2018-214229","article-title":"Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial","volume":"78","author":"Rosenzwajg","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2019.04.020_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002139","article-title":"Regulatory T cell responses in participants with type 1 diabetes after a single dose of interleukin-2: a non-randomised, open label, adaptive dose-finding trial","volume":"13","author":"Todd","year":"2016","journal-title":"Plos Med"},{"key":"10.1016\/j.clinthera.2019.04.020_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/2e462817-ab93-4d78-95a4-1d8b9d172971","article-title":"Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis","volume":"7","author":"Sokolove","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2019.04.020_bib39","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00281-017-0627-z","article-title":"The role of autoantibodies in the pathophysiology of rheumatoid arthritis","volume":"39","author":"Derksen","year":"2017","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.clinthera.2019.04.020_bib40","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1136\/ard.2009.119016","article-title":"Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)","volume":"69","author":"Emery","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2019.04.020_bib41","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.semarthrit.2018.09.008","article-title":"Therapeutic tolerance in autoimmune disease","volume":"48","author":"Rayner","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2019.04.020_bib42","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.berh.2013.09.001","article-title":"Early rheumatoid arthritis: the performance of the 2010 ACR\/EULAR criteria for diagnosing RA","volume":"27","author":"Mjaavatten","year":"2013","journal-title":"Best Pract Res"},{"key":"10.1016\/j.clinthera.2019.04.020_bib43","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1056\/NEJMoa043980","article-title":"Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes","volume":"352","author":"Keymeulen","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2019.04.020_bib44","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1479-5876-5-27","article-title":"Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis","volume":"5","author":"Chamian","year":"2007","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.clinthera.2019.04.020_bib45","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/BOR.0000000000000029","article-title":"Prospects for therapeutic tolerance in humans","volume":"26","author":"Baker","year":"2014","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.clinthera.2019.04.020_bib46","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","article-title":"Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases","volume":"12","author":"Schwartz","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.clinthera.2019.04.020_bib47","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.coi.2016.09.003","article-title":"Targeting B cells in treatment of autoimmunity","volume":"43","author":"Franks","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.clinthera.2019.04.020_bib48","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1136\/annrheumdis-2017-212763","article-title":"Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study","volume":"78","author":"Gerlag","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2019.04.020_bib49","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1084\/jem.20040165","article-title":"Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF alpha therapy","volume":"200","author":"Ehrenstein","year":"2004","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.clinthera.2019.04.020_bib50","doi-asserted-by":"crossref","first-page":"12099","DOI":"10.1073\/pnas.0705268104","article-title":"IL-6-dependent and -independent pathways in the development of interleukin 17-producing T helper cells","volume":"104","author":"Kimura","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinthera.2019.04.020_bib51","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1002\/art.27638","article-title":"The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an age-dependent manner","volume":"62","author":"Deane","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2019.04.020_bib52","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/art.27186","article-title":"Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis","volume":"62","author":"Kokkonen","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2019.04.020_bib53","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/annrheumdis-2016-210624","article-title":"A\u00a0randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis","volume":"76","author":"Burmester","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2019.04.020_bib54","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1136\/annrheumdis-2014-206598","article-title":"Extensive glycosylation of ACPA-IgG variable domains modulates binding to citrullinated antigens in rheumatoid arthritis","volume":"75","author":"Rombouts","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2019.04.020_bib55","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/ni.3579","article-title":"Regulation of autoantibody activity by the IL-23-TH17 axis determines the onset of autoimmune disease","volume":"18","author":"Pfeifle","year":"2017","journal-title":"Nat Immunol"},{"key":"10.1016\/j.clinthera.2019.04.020_bib56","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/art.22525","article-title":"Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial","volume":"56","author":"van Dongen","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2019.04.020_bib57","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1136\/ard.2009.119149","article-title":"Beneficial effects of a 3-week course of intramuscular glucocorticoid injections in patients with very early inflammatory polyarthritis: results of the STIVEA trial","volume":"69","author":"Verstappen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2019.04.020_bib58","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/ard.2009.122473","article-title":"The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis","volume":"69","author":"Machold","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2019.04.020_bib59","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1002\/art.40062","article-title":"Brief report: clinical trials aiming to prevent rheumatoid arthritis cannot detect prevention without adequate risk stratification: a trial of methotrexate versus placebo in undifferentiated arthritis as an example","volume":"69","author":"Burgers","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.clinthera.2019.04.020_bib60","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/ard.2008.105767","article-title":"Effect of dexamethasone on autoantibody levels and arthritis development in patients with arthralgia: a randomised trial","volume":"69","author":"Bos","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2019.04.020_bib61","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nrrheum.2016.175","article-title":"Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers","volume":"12","author":"Brown","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.clinthera.2019.04.020_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2249.2012.04623.x","article-title":"CD73 and adenosine generation in the creation of regulatory microenvironments","volume":"171","author":"Regateiro","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.clinthera.2019.04.020_bib63","doi-asserted-by":"crossref","first-page":"732","DOI":"10.4049\/jimmunol.1103601","article-title":"Transient low-dose methotrexate induces tolerance to murine anti-thymocyte globulin and together they promote long-term allograft survival","volume":"189","author":"Joseph","year":"2012","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.clinthera.2019.04.020_bib64","doi-asserted-by":"crossref","first-page":"7370","DOI":"10.1038\/s41598-018-24240-2","article-title":"Analysis of early changes in DNA methylation in synovial fibroblasts of RA patients before diagnosis","volume":"8","author":"Karouzakis","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.clinthera.2019.04.020_bib65","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1002\/art.1780391103","article-title":"Invasive fibroblast-like synoviocytes in rheumatoid arthritis. Passive responders or transformed aggressors?","volume":"39","author":"Firestein","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2019.04.020_bib66","doi-asserted-by":"crossref","first-page":"11125","DOI":"10.1038\/s41598-018-29127-w","article-title":"Evaluating the bromodomain protein BRD1 as a therapeutic target in rheumatoid arthritis","volume":"8","author":"Klein","year":"2018","journal-title":"Sci Rep"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819301845?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819301845?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:51:05Z","timestamp":1758963065000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291819301845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":66,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0149291819301845"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.04.020","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential Pharmacologic Targets for the Prevention of Rheumatoid Arthritis","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.04.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}